Trade Zentalis Pharmaceuticals - ZNTL CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.11 |
| Open | 3.17 |
| 1-Year Change | -78.35% |
| Day's Range | 2.95 - 3.17 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 17, 2024 | 3.11 | 0.08 | 2.64% | 3.03 | 3.22 | 3.01 |
| Dec 16, 2024 | 3.08 | -0.01 | -0.32% | 3.09 | 3.23 | 3.02 |
| Dec 13, 2024 | 3.07 | 0.10 | 3.37% | 2.97 | 3.16 | 2.95 |
| Dec 12, 2024 | 3.13 | -0.21 | -6.29% | 3.34 | 3.50 | 3.10 |
| Dec 11, 2024 | 3.47 | -0.12 | -3.34% | 3.59 | 3.69 | 3.43 |
| Dec 10, 2024 | 3.58 | -0.16 | -4.28% | 3.74 | 3.84 | 3.57 |
| Dec 9, 2024 | 3.86 | 0.35 | 9.97% | 3.51 | 3.97 | 3.49 |
| Dec 6, 2024 | 3.47 | 0.21 | 6.44% | 3.26 | 3.55 | 3.26 |
| Dec 5, 2024 | 3.31 | 0.07 | 2.16% | 3.24 | 3.44 | 3.21 |
| Dec 4, 2024 | 3.37 | 0.09 | 2.74% | 3.28 | 3.43 | 3.20 |
| Dec 3, 2024 | 3.34 | -0.27 | -7.48% | 3.61 | 3.61 | 3.26 |
| Dec 2, 2024 | 3.64 | -0.02 | -0.55% | 3.66 | 3.89 | 3.58 |
| Nov 29, 2024 | 3.59 | -0.04 | -1.10% | 3.63 | 3.70 | 3.59 |
| Nov 27, 2024 | 3.62 | 0.15 | 4.32% | 3.47 | 3.68 | 3.46 |
| Nov 26, 2024 | 3.46 | 0.08 | 2.37% | 3.38 | 3.53 | 3.36 |
| Nov 25, 2024 | 3.46 | 0.22 | 6.79% | 3.24 | 3.58 | 3.24 |
| Nov 22, 2024 | 3.21 | 0.11 | 3.55% | 3.10 | 3.39 | 3.05 |
| Nov 21, 2024 | 3.16 | 0.13 | 4.29% | 3.03 | 3.22 | 2.90 |
| Nov 20, 2024 | 3.12 | 0.22 | 7.59% | 2.90 | 3.17 | 2.88 |
| Nov 19, 2024 | 2.97 | -0.03 | -1.00% | 3.00 | 3.05 | 2.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Zentalis Pharmaceuticals Company profile
About Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It is developing a pipeline of product candidates with a focus on validated oncology targets. Its lead product candidates, ZN-c5, is an oral selective estrogen receptor degrader. ZN-c5 is in a Phase I/II clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative and ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase. ZN-c3 is in a Phase I/II clinical trial for the treatment of advanced solid tumors. Its other products include ZN-d5, a selective inhibitor of B-cell lymphoma 2, in development for the treatment of non-Hodgkin’s lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, in a Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Zentalis Pharmaceuticals Inc revenues was not reported. Net loss increased 35% to $158.7M. Higher net loss reflects Research & Development Expense - Balanci increase of 88% to $145.9M (expense), Stock-based Compensation in R&D increase from $7.3M to $20.9M (expense), Selling, General & Administrative Expens increase of 31% to $23.7M (expense).
| Industry: | Bio Therapeutic Drugs |
1359 Broadway, Suite 801
NEW YORK
NEW YORK 10018
US
News
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
22:39, 12 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
12:47, 5 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com